СУРУНКАЛИ БУЙРАК КАСАЛЛИГИДА ГИПОАЗОТЕМИК ПРЕПАРАТЛАРНИНГ ЛИПИДЛАР СПЕКТРИГА ТАЪСИРИ

The article presents the results of a study have 123 patients with predialysis stage of chronic kidney disease. The blood lipid spectrum (cholesterol, LDL, HDL, triglycerides) was evaluated. The results showed that dyslipidemia in stage III of CKD is observed at least, and in stage IV it is more pronounced and this is expressed by an increase in the levels of CS, LDL, TG and a decrease in HDL. When using the hypo-azotemic drug nephrotisin, there is an improvement in kidney function with optimization of dyslipidemia indicators.